Peptides›Cosmetic›Syn-Ake

Syn-Ake

/ Synthetic tripeptide; INCI 'Tripeptide-3'; beta-Ala-Pro-Dab-NHBn benzylamide; snake-venom (waglerin) mimetic

SPECULATIVEN = 0 · TESTING PENDING

ALIAS · Syn-Ake (trade — Pentapharm/DSM) · Tripeptide-3 (INCI) · beta-Ala-Pro-Dab-NHBn

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequencebeta-Ala-Pro-Dab-NHBn

MW · —CLASS · Synthetic tripeptide; INCI 'Tripeptide-3'; beta-Ala-Pro-Dab-NHBn benzylamide; snake-venom (waglerin) mimeticCATEGORY · Cosmetic

Tier 4. Syn-Ake is the trade name (Pentapharm, now part of DSM) for a synthetic tripeptide marketed as Tripeptide-3 under INCI nomenclature, structurally derived from the snake-venom peptide waglerin-1. Cosmetic positioning is as a topical 'Botox-alternative' active. The mechanistic class (waglerin-derived nAChR antagonism) is real; topical-efficacy claims in cosmetic application rest predominantly on industry-authored studies.

§ B · Mechanism of action

Syn-Ake is a beta-alanyl-prolyl-(2,4-diaminobutyric acid) benzylamide tripeptide, designed as a minimal mimetic of the waglerin-1 nicotinic acetylcholine receptor antagonist pharmacophore. The proposed cosmetic mechanism is competitive antagonism at the muscle-type nAChR (alpha-1 / epsilon subunit interface) of facial mimetic-muscle neuromuscular junctions, attenuating acetylcholine-driven contraction. Whether topical application produces meaningful epidermal or dermal penetration to underlying neuromuscular junctions has not been established in independent pharmacokinetic studies.

§ C · Human clinical evidence

Tier 4. The mechanistic class derives from solid waglerin nAChR pharmacology (Sellin and colleagues, 1990s). Cosmetic topical-efficacy studies are largely supplier-sponsored. Independent randomised work versus placebo at supplier-recommended concentrations is limited in the indexed primary literature.

§ D · Primary literature

PubMed8770182Sellin LC et al. — Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor · Biophysical Journal · in-vitroConformational and electrophysiological characterisation of waglerin demonstrating competitive antagonism at the muscle-type nicotinic acetylcholine receptor; mechanistic basis for downstream Syn-Ake-class mimetics.Limitations: In-vitro / structural; not a topical-efficacy study; does not establish cosmetic dermal-penetration claims.1996

§ F · Safety signal

No formal independent safety database beyond supplier patch-test data. Systemic exposure from topical application is presumed low but has not been quantified. Theoretical concern from the nAChR-antagonist mechanism applies as for the diacetate form; cosmetic doses are asserted to be far below thresholds for systemic neuromuscular effect.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Confusion between Syn-Ake (Tripeptide-3) and the related extended INCI form Dipeptide Diaminobutyroyl Benzylamide Diacetate is common in vendor and consumer literature; both are sold under Syn-Ake / waglerin-mimetic branding. Topical efficacy versus placebo at cosmetic-product concentrations has not been established in independent randomised work.